ClinicalTrials.gg
TerminatedNCT04810208Updated Dec 30, 2021

Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours

A Phase 1 interventional study of Docetaxel in Solid Tumor, sponsored by Lidds AB. Terminated at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-30.

Sponsored by Lidds AB · Phase 1, Interventional, and Treatment

Why this study was terminated
Strategic decision

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Feb 2019, registered Mar 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicentre, open-label, first in man, study of a novel NanoZolid®-docetaxel depot formulation (NZ-DTX Depot) given as an intra-tumoural injection in patients with advanced solid tumours. The study includes a dose escalation part and a dose expansion part.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Lidds AB is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed written granted before undertaking any study-specific procedures;
  2. Male or female patient ≥18 years of age on the day of consenting to the study;
  3. or cytologically confirmed diagnosis of solid cancer;
  4. At least 1 advanced solid, palpable, cutaneous or subcutaneous tumour lesion with following characteristics:

    • a cutaneous lesion with of thickness ≥4 mm and diameter ≥25 mm at the longest axis, or
    • a subcutaneous lesion of diameter ≥20 mm at the longest and the shortest axis;
  5. Eastern Co-operative Oncology Group () performance status (PS) 0-2;
  6. Patient from one the following categories:

    • Patient for whom no standard therapy exists, or standard therapy is , or
    • Patient who is scheduled for other anti-cancer treatment (e.g. radiotherapy, immunological treatment, surgery) which will start after completion of at least one treatment cycle of NZ-DTX, i.e after the end-of-study (EOS) visit.

Exclusion criteria

Exclusion Criteria:

  1. Known to any of the in the NZ-DTX Depot formulation (docetaxel, calcium sulphate, sodium carboxymethylcellulose);
  2. \<3 months;
  3. Bleeding deficiencies or ongoing anticoagulant therapy that would put the patient at increased risk of bleeding, in the judgement of the Investigator. If the patient has an (INR) below 1.2 the Investigator may judge if interruption of anticoagulant therapy is warranted;
  4. Any of the following abnormal laboratory values at screening;

    • Bone marrow function:

      • (ANC) \<1.5 x 109/l;
      • count \<100 x 109/l;
      • \<9.0 mg/dl.
    • Coagulation:

      • International Normalized Ratio (INR) >1.2.
    • Hepatic, renal, and biochemistry parameters:

      • (AST) or alanine transaminase (ALT) >2.5 x (ULN) (>5 x ULN if liver present)*;
      • Alkaline phosphatase (ALP) >2.5 x ULN;
      • Total >1.5 x ULN;
      • Estimated (eGFR) \<40 ml/min/1.73 m² using the Modified Cockcroft \& Gault formula.

        • For patients with liver impairment who have serum transaminase levels (ALT and/or AST) greater than 1.5 times x ULN - the doses will be restricted to max. 75mg/m2. In the event this is not possible the patient will not be included.
  5. Severe fluid retention, e.g. pulmonary oedema, pleural effusion, pericardial effusion or ascites;
  6. Clinically significant heart disease (i.e. heart failure or myocardial infarction within 6 months of screening, instable angina pectoris);
  7. History of thromboembolic or cerebrovascular events within 6 months of screening;
  8. Major surgery within 2 weeks of screening, or patient not recovered from major surgery;
  9. Known untreated or uncontrolled acute infection, including urinary tract infection, within 7 days of screening;
  10. Not recovered from Grade 2 or higher adverse events (AEs) due to previous treatments, excepting alopecia;
  11. Concurrent participation in another study;
  12. Last investigational drug administration in a prior investigational study within 14 days of study treatment initiation or \<5 times the half-life of the investigational drug, whichever is longer;
  13. Last administration of other anti-neoplastic drug within 14 days of study treatment initiation;
  14. Radiotherapy of lesion to be injected within 4 weeks of first treatment with NZ-DTX Depot, or irradiated lesion to be injected without signs of disease progression since irradiation;
  15. For men and women of : Unwillingness to follow requirements;
  16. Female patients with planned or current pregnancy and/or currently breastfeeding;
  17. Any other severe, acute or chronical medical or psychiatric condition or laboratory abnormality that, in the judgement of the Investigator, would make the patient inappropriate for study participation.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    NZ-DTX Depot

    Drug: Docetaxel

Interventions

  • Docetaxel in NanoZolid formulation, for intratumoural injection

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) of NZ-DTX Depot given as an intra-tumoural injection in solid, palpable, cutaneous or subcutaneous tumour lesions.

    The MTD will be determined by incidence of DLTs

    Time frame: 5 weeks

  2. The recommended Phase 2 dose (RP2D) of NZ-DTX Depot given as an intra-tumoural injection in a solid, palpable cutaneous or subcutaneous tumour lesion.

    The RP2D will be determined by frequency and severity of adverse events

    Time frame: 5 weeks

Secondary outcomes

  1. Frequency and severity of treatment-emergent adverse events [safety and tolerability] following an intratumoural injection of NZ-DTX Depot

    Frequency and severity of treatment-emergent adverse events

    Time frame: 5 weeks

  2. Plasma concentration of docetaxel, following an intratumoural injection of NZ-DTX Depot

    Plasma concentration of docetaxel

    Time frame: 5 weeks

  3. Anti-tumour effect following an intratumoural injection of NZ-DTX Depot

    Tumour response by RECIST

    Time frame: 5 weeks

Other outcomes

  1. Presence of immune biomarkers in plasma, following an intratumoural injection of NZ-DTX Depot

    Analysis of cytokines in plasma

    Time frame: 9 weeks

  2. Presence of immune biomarkers in tissue, following an intratumoural injection of NZ-DTX Depot

    Immunohistochemistry analysis \[PD-L1\] in tissue

    Time frame: 9 weeks

07

Study locations

4 sites
  • Herlev Hospital
    Copenhagen, Denmark
  • Lithuanian University of Health Sciences
    Kaunas, Lithuania
  • National Cancer Institute
    Vilnius, Lithuania
  • Karolinska University Hospital
    Stockholm, Sweden
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Oct 2021, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2021
First posted
Mar 22, 2021
StartActual
Feb 28, 2019
Primary completionActual
Oct 7, 2021
CompletionActual
Oct 7, 2021
Last update
Dec 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04810208
Lead sponsor
Lidds AB
Responsible party
Sponsor
First posted
Mar 22, 2021
Start date
Feb 28, 2019
Primary completion
Oct 7, 2021
Completion
Oct 7, 2021
Last update
Dec 30, 2021

Study contacts

Charlotta Gauffin, PhD
study director · Lidds AB

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion